Please provide your email address to receive an email when new articles are posted on . Patients with nasopharyngeal cancer who received morning radiotherapy survived longer than those treated later ...

As a first-line therapy, the risk of disease progression or death was reduced by 55% in the pempulimab-kcqx group vs the placebo group. The Food and Drug Administration (FDA) has approved ...

KUALA LUMPUR, Feb 12 (Bernama) -- Persistent nasal congestion, unexplained ear symptoms such as blocked hearing, ringing in the ears, or painless neck lumps are often dismissed as common ear, nose and ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with ...

Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

The TP63 gene, an important member of the TP53 family, contains two independent promoters that drive the transcription of TAp63 and ΔNp63, respectively. Through alternative splicing, TAp63 and ΔNp63 ...

Loqtorzi combined with chemotherapy nearly doubled median overall survival in nasopharyngeal carcinoma patients compared to chemotherapy alone, with a median survival of 64.8 months. The combination ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Individuals ...

MRI showed more than 90% sensitivity in detecting nasopharyngeal carcinoma (NPC), surpassing endoscopy’s detection rate of 65.6% over a 5-year period. MRI particularly excelled in identifying ...

(RTTNews) - Biopharmaceutical company Akeso Inc. (AKESF) said in a statement that its Penpulimab has been approved for the first-line treatment of recurrent or metastatic nasopharyngeal cancer or NPC, ...